Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
Garnsey, M. R.; Robinson, M. C.; Nguyen, L. T.; Cardin, R.; Tillotson, J.; Mashalidis, E.; Aijia, Y.; Aschenbrenner, L.; Balesano, A.; Behzadi, A.; Boras, B.; Chang, J. S.; Eng, H.; Ephron, A.; Foley, T.; Ford, K.; Frick, J. M.; Gibson, S.; Li, H.; Hurst, B.; Kalgutkar, A. S.; Korczynska, M.; Lengyel-Zhand, Z.; Liping, G.; Meredith, H. R.; Patel, N. C.; Polivkova, J.; Rai, D.; Rose, C. R.; Rothan, H.; Sakata, S. K.; Vargo, T. R.; Qi, W.; Wu, H.; Liu, Y.; Yurgelonis, I.; Zhang, J.; Zhu, Y.; Zhang, L.; Lee, A. A.
Show abstract
Vaccines and first-generation antiviral therapeutics have provided important protection against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PLpro) is one of two essential cysteine proteases involved in viral replication. While inhibitors of the SARS-CoV-2 main protease (Mpro) have demonstrated clinical efficacy, known PLpro inhibitors have to date lacked the inhibitory potency and requisite pharmacokinetics to demonstrate that targeting PLpro translates to in vivo efficacy in a preclinical setting. Herein, we report the machine learning-driven discovery of potent, selective, and orally available SARS-CoV-2 PLpro inhibitors, with lead compound PF-07957472 (4) providing robust efficacy in a mouse-adapted model of COVID-19 infection.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis 93%
- A novel inhibitor against the bromodomain PfBDP1 of the malaria pathogen Plasmodium falciparum 93%
- Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening 93%
Similar papers in this journal
- Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP 94%
- Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses 94%
- Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities 93%
Similar papers in this journal
- Chemical validation of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase using fragment linking and CRISPR interference 94%
- Discovery and biosynthesis of biffamycin A, a novel glycotetrapeptide antibiotic 93%
- Structure-based Evolution of G protein-biased μ-opioid Receptor Agonists 93%
Similar papers in this journal
- Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling 93%
- Transfer learning enables discovery of sub-micromolar antibacterials for ESKAPE pathogens from ultra-large chemical spaces 92%
- Structure-Aware Dual-Target Drug Design through Collaborative Learning of Pharmacophore Combination and Molecular Simulation 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.